Helix D elongation and allosteric activation of antithrombin

被引:45
作者
Belzar, KJ
Zhou, AW
Carrell, RW
Gettins, PGW
Huntington, JA
机构
[1] Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Wellcome Trust, Cambridge CB2 2XY, England
[2] Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA
关键词
D O I
10.1074/jbc.M110807200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Antithrombin requires allosteric activation by heparin for efficient inhibition of its target protease, factor Xa. A pentasaccharide sequence found in heparin activates antithrombin by inducing conformational changes that affect the reactive center of the inhibitor resulting in optimal recognition by factor Xa. The mechanism of transmission of the activating conformational change from the heparin-binding region to the reactive center loop remains unresolved. To investigate the role of helix D elongation in the allosteric activation of antithrombin, we substituted a proline residue for Lys(133). Heparin binding affinity was reduced by 25-fold for the proline variant compared with the control, and a significant decrease in the associated intrinsic fluorescence enhancement was also observed. Rapid kinetic studies revealed that the main reason for the reduced affinity for heparin was an increase in the rate of the reverse conformational change step. The pentasaccharide-accelerated rate of factor Xa inhibition for the proline variant was 10-fold lower than control, demonstrating that the proline variant cannot be fully activated toward factor Xa. We conclude that helix D elongation is critical for the full conversion of antithrombin to its high affinity, activated state, and we propose a mechanism to explain how helix D elongation is coupled to allosteric activation.
引用
收藏
页码:8551 / 8558
页数:8
相关论文
共 43 条
[1]   CRYSTALLIZATION AND X-RAY-DIFFRACTION DATA OF THE CLEAVED FORM OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 [J].
AERTGEERTS, K ;
DEBONDT, HL ;
DERANTER, C ;
DECLERCK, PJ .
PROTEINS-STRUCTURE FUNCTION AND GENETICS, 1995, 23 (01) :118-121
[2]  
BAGLIN TP, 2001, THROMB HAEMOSTASIS S
[3]  
BJORK I, 1992, J BIOL CHEM, V267, P19047
[4]   BIOLOGICAL IMPLICATIONS OF A 3-ANGSTROM STRUCTURE OF DIMERIC ANTITHROMBIN [J].
CARRELL, RW ;
STEIN, PE ;
WARDELL, MR ;
FERMI, G .
STRUCTURE, 1994, 2 (04) :257-270
[5]   Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence - Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin [J].
Chuang, YJ ;
Swanson, R ;
Raja, SM ;
Olson, ST .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (18) :14961-14971
[6]   The antithrombin P1 residue is important for target proteinase specificity but not for heparin activation of the serpin. Characterization of P1 antithrombin variants with altered proteinase specificity but normal heparin activation [J].
Chuang, YJ ;
Swanson, R ;
Raja, SM ;
Bock, SC ;
Olson, ST .
BIOCHEMISTRY, 2001, 40 (22) :6670-6679
[7]   Topography of a 2.0 Å structure of α1-antitrypsin reveals targets for rational drug design to prevent conformational disease [J].
Elliott, PR ;
Pei, XY ;
Dafforn, TR ;
Lomas, DA .
PROTEIN SCIENCE, 2000, 9 (07) :1274-1281
[8]   Wild-type α1-antitrypsin is in the canonical inhibitory conformation [J].
Elliott, PR ;
Abrahams, JP ;
Lomas, DA .
JOURNAL OF MOLECULAR BIOLOGY, 1998, 275 (03) :419-425
[9]   Serine 380 (P14) → glutamate mutation activates antithrombin as an inhibitor of factor Xa [J].
Futamura, A ;
Gettins, PGW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (06) :4092-4098
[10]  
Gettins P.G.W., 1996, SERPINS STRUCTURE FU